Product Description
Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31800988/)
Mechanisms of Action: CGRP Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Israel | Saudi Arabia | United Arab Emirates | United States
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: Eastern America
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Puerto Rico, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Migraine Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05125302 |
Ubro Peds | P3 |
Recruiting |
Migraine Disorders |
2026-05-01 |
24% |
2025-01-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06578585 |
20527A | P1 |
Completed |
Migraine Disorders |
2025-07-11 |
50% |
2025-10-15 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05127954 |
UBRO PEDS OLE | P3 |
Enrolling by invitation |
Migraine Disorders |
2028-01-01 |
64% |
2025-07-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06417775 |
UBRO MM | P3 |
Recruiting |
Migraine Disorders |
2027-06-01 |
38% |
2025-10-28 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/14/2024 |
News Article |
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments |
|
05/08/2024 |
News Article |
QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults |
|
03/20/2024 |
News Article |
Deerfield Agency Welcomes Bill Veltre as EVP, Head of Media |
|
11/29/2023 |
News Article |
Pfizer's Nurtec Receives Top Ranking in 2023 TGaS Digital Marketing Competency Report |